Vanda Pharmaceuticals (VNDA) closed at $4.15 on November 11, 2026, up 1.7% from the previous close, on volume of 666,995 shares (30-day average 1,233,888).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Call Spread | 16-Oct : 20-Nov-26 4 C | 500 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
NEREUS - The Goat of Biscayne Bay Arrives for Miami Art Week
PRNewswire (Wed, 11-Nov 9:01 AM ET)
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
PRNewswire (Tue, 3-Nov 4:30 PM ET)
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
PRNewswire (Wed, 28-Oct 4:01 PM ET)
PRNewswire (Tue, 27-Oct 6:50 AM ET)
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
PRNewswire (Wed, 21-Oct 5:41 PM ET)
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
PRNewswire (Wed, 14-Oct 5:01 PM ET)
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
PRNewswire (Fri, 2-Oct 9:07 AM ET)
VNDA spotlights Phase III HETLIOZ data: 37.1-minute sleep-onset improvement versus placebo in DSWPD
Market Chameleon (Wed, 30-Sep 3:06 AM ET)
PRNewswire (Tue, 29-Sep 6:46 PM ET)
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
PRNewswire (Wed, 2-Sep 4:52 PM ET)
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Vanda Pharmaceuticals trades on the NASDAQ stock market under the symbol VNDA.
As of November 11, 2026, VNDA stock price climbed to $4.15 with 666,995 million shares trading.
VNDA has a beta of 0.59, meaning it tends to be less sensitive to market movements. VNDA has a correlation of 0.01 to the broad based SPY ETF.
VNDA has a market cap of $250.95 million. This is considered a Small Cap stock.
Last quarter Vanda Pharmaceuticals reported $70 million in Revenue and -$.37 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.32.
In the last 3 years, VNDA traded as high as $9.94 and as low as $3.32.
The top ETF exchange traded funds that VNDA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
VNDA has underperformed the market in the last year with a return of -6.1%, while the SPY ETF gained +12.6%. In the last 3 month period, VNDA fell short of the market, returning -17.3%, while SPY returned -1.5%. However, in the most recent 2 weeks VNDA has outperformed the stock market by returning +4.0%, while SPY returned -1.3%.
VNDA support price is $3.92 and resistance is $4.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNDA shares will trade within this expected range on the day.
